Back to Search
Start Over
Current state of CAR-T therapy for T-cell malignancies
- Source :
- Therapeutic Advances in Hematology, Vol 13 (2022)
- Publication Year :
- 2022
- Publisher :
- SAGE Publishing, 2022.
-
Abstract
- Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteristic of high heterogeneity and poor prognoses. The efficacy of current treatments for this group of diseases is limited. CAR-T therapy is a promising solution to ameliorate the current therapeutic situation. One of the major challenges is that normal T-cells typically share mutual antigens with malignant cells, which causes fratricide and serious T-cell aplasia. Moreover, T-cells collected for CAR transduction could be contaminated by malignant T-cells. The selection of suitable target antigens is of vital importance to mitigate fratricide and T-cell aplasia. Using nanobody-derived or naturally selected CAR-T is the latest method to overcome fratricide. Allogeneic CAR-T products and CAR-NK-cells are expected to avoid tumor contamination. Herein, we review the advances in promising target antigens, the current results of CAR-T therapy clinical trials in T-cell malignancies, the obstacles of CAR-T therapy in T-cell malignancies, and the solutions to these issues.
- Subjects :
- Diseases of the blood and blood-forming organs
RC633-647.5
Subjects
Details
- Language :
- English
- ISSN :
- 20406215 and 20406207
- Volume :
- 13
- Database :
- Directory of Open Access Journals
- Journal :
- Therapeutic Advances in Hematology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.bf21efffc30c4f1e847586845485cee1
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/20406207221143025